NBIX
Closed
Neurocrine Biosciences Inc
128.
+2 (+1.59%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 125.69
Day's Range: 126.15 - 129.27
Send
sign up or login to leave a comment!
When Written:
104.77
Neurocrine Biosciences Inc. is a biopharmaceutical company that specializes in developing treatments for neurological, endocrine, and psychiatric disorders. The company was founded in 1992 and is headquartered in San Diego, California.
Neurocrine Biosciences has several products on the market, including Ingrezza (valbenazine) for the treatment of tardive dyskinesia and Ongentys (opicapone) for Parkinson's disease. The company also has several products in clinical development, including treatments for schizophrenia, depression, and rare genetic disorders.
Neurocrine Biosciences has partnerships with several other pharmaceutical companies, including AbbVie, Takeda, and Janssen. The company's mission is to improve the lives of patients suffering from neurological and endocrine disorders through innovative research and development.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Neurocrine Biosciences has several products on the market, including Ingrezza (valbenazine) for the treatment of tardive dyskinesia and Ongentys (opicapone) for Parkinson's disease. The company also has several products in clinical development, including treatments for schizophrenia, depression, and rare genetic disorders.
Neurocrine Biosciences has partnerships with several other pharmaceutical companies, including AbbVie, Takeda, and Janssen. The company's mission is to improve the lives of patients suffering from neurological and endocrine disorders through innovative research and development.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








